Shulman Lee P, Harari David
Departments of Obstetrics and Gynecology and Molecular Genetics, and Division of Reproductive Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60611, USA.
Menopause. 2004 Jan-Feb;11(1):34-9. doi: 10.1097/01.GME.0000074705.98544.16.
To determine whether low-dose transdermal estrogen therapy is associated with a reduction in vasomotor symptoms in women who continue to have menstrual cycles.
An open-label, observational evaluation conducted over 12 months in 22 consecutive perimenopausal women with vasomotor symptoms.
Improvement in vasomotor symptoms was reported by 16 (73%) of women evaluated. Of responders, 11 characterized symptom relief as complete and 6 as moderate. Fifteen (68%) of the women remained on transdermal estrogen at 12 months. No adverse health-related events were attributed to estrogen therapy.
Low-dose transdermal estrogen is well tolerated and was associated with a reduction in complaints of vasomotor symptoms before menopause. The steady-state pharmacokinetics of transdermal delivery of unopposed estrogen may be advantageous in a population sensitive to fluctuations in circulating hormone levels.
确定低剂量经皮雌激素疗法是否与仍有月经周期的女性血管舒缩症状的减轻相关。
对22名连续的有血管舒缩症状的围绝经期女性进行为期12个月的开放标签观察性评估。
在接受评估的女性中，16名（73%）报告血管舒缩症状有所改善。在有反应者中，11名称症状完全缓解，6名称症状中度缓解。15名（68%）女性在12个月时仍在使用经皮雌激素。未发现与雌激素治疗相关的不良健康事件。
低剂量经皮雌激素耐受性良好，且与绝经前血管舒缩症状的主诉减少相关。在对循环激素水平波动敏感的人群中，非对抗性雌激素经皮给药的稳态药代动力学可能具有优势。
